Gelesis Holdings Inc GLSHQ
About Quantitative Ratings
Morningstar Quantitative Ratings for Stocks are generated using an algorithm that compares companies that are not under analyst coverage to peer companies that do receive analyst-driven ratings. Companies with quantitative ratings are not formally covered by a Morningstar analyst, but are statistically matched to analyst-rated companies, allowing our models to calculate a quantitative moat, fair value, and uncertainty rating.
Trading Information
- Previous Close Price
- $0.02
- Day Range
- $0.00–0.01
- 52-Week Range
- $0.00–0.07
- Bid/Ask
- $0.00 / $0.01
- Market Cap
- $73.34
- Volume/Avg
- 200 / 32,997
Key Statistics
- Price/Earnings (Normalized)
- —
- Price/Sales
- 0.01
- Dividend Yield (Trailing)
- —
- Dividend Yield (Forward)
- —
- Total Yield
- —
Company Profile
Gelesis Holdings Inc is a biotherapeutics company advancing a novel category of treatments for weight management and gut related chronic diseases. Its portfolio includes Plenity, an FDA-cleared product to aid in weight management, as well as potential therapies in development for patients with Type 2 Diabetes, Non-alcoholic Fatty Liver Disease (NAFLD)/Non-alcoholic Steatohepatitis (NASH), and Functional Constipation.
- Sector
- Healthcare
- Industry
- Biotechnology
- Stock Style Box
- —
- Total Number of Employees
- 93
- Website
- https://www.gelesis.com
Valuation
|
Metric
|
GLSHQ
|
|---|---|
Price/Earnings (Normalized) | — |
Price/Book Value | — |
Price/Sales | 0.01 |
Price/Cash Flow | — |
Price/Earnings
GLSHQ
Financial Strength
|
Metric
|
GLSHQ
|
|---|---|
Quick Ratio | 0.35 |
Current Ratio | 0.49 |
Interest Coverage | −22.46 |
Quick Ratio
GLSHQ
Profitability
|
Metric
|
GLSHQ
|
|---|---|
Return on Assets (Normalized) | −43.72% |
Return on Equity (Normalized) | — |
Return on Invested Capital (Normalized) | −93.41% |
Return on Assets
GLSHQ
Biotechnology Industry Comparables
|
Ticker
|
Name
|
Morningstar Rating for Stocks
|
Capital Allocation
|
Economic Moat
|
Market Cap
|
|---|---|---|---|---|---|
NVO
| Novo Nordisk A/S ADR | Thdvqzhb | Qvw | $567.0 Bil | |
VRTX
| Vertex Pharmaceuticals Inc | Fhxyxjkc | Dwbjj | $109.1 Bil | |
REGN
| Regeneron Pharmaceuticals Inc | Gxvdrgf | Zdgftq | $105.3 Bil | |
MRNA
| Moderna Inc | Fgdlwfnwm | Pynq | $47.0 Bil | |
ARGX
| argenx SE ADR | Mckjntck | Jrx | $22.3 Bil | |
BNTX
| BioNTech SE ADR | Jxfffpwn | Bzlvg | $22.1 Bil | |
ALNY
| Alnylam Pharmaceuticals Inc | Snhxjgdp | Bpdsdy | $19.0 Bil | |
BMRN
| Biomarin Pharmaceutical Inc | Rfgbfrnyt | Zqjqvg | $15.5 Bil | |
RPRX
| Royalty Pharma PLC Class A | Kjyscdvn | Lsszh | $12.7 Bil | |
INCY
| Incyte Corp | Ynxlgqlt | Xgrmty | $12.0 Bil |